The Cost-Effectiveness of Imlifidase Idefirix® for Desensitization Treatment of Highly Sensitized Adult Kidney Transplant Patients in Ireland
Author(s)
Véronique Lauzon, MA1, Will Wright, PhD2, Daniel Evans, MSc2, Marcus Dahlman, BSc, MBA3, Gina Ewy, MHA, JD4, Benjamin Oskar, MSc3.
1International Market Access, Montréal, QC, Canada, 2FIECON, London, United Kingdom, 3Hansa Biopharma, Lund, Sweden, 4Hansa Biopharma, Chapel Hill, NC, USA.
1International Market Access, Montréal, QC, Canada, 2FIECON, London, United Kingdom, 3Hansa Biopharma, Lund, Sweden, 4Hansa Biopharma, Chapel Hill, NC, USA.
OBJECTIVES: Imlifidase is the only desensitisation treatment (conditionally) approved in Europe to enable kidney transplantation in highly sensitised adult patients who are a positive crossmatch against an available deceased donor kidney. Without imlifidase, highly sensitised patients potentially face a lifetime on dialysis. An economic model was developed from the Irish healthcare system perspective to determine whether imlifidase-enabled kidney transplantation is a cost-effective use of resources compared to current standard of care (long-term dialysis).
METHODS: A Markov model was developed to estimate the lifetime costs and quality-adjusted life years (QALYs) for imlifidase-enabled transplantation versus long-term dialysis in Ireland. The model was developed in line with National Centre for Pharmacoeconomics guidelines and consisted of three health states aligned to the local pathway of care: (1) Dialysis (all types); (2) Functioning Graft; and (3) Death. Patients accrue costs, life years, and QALYs in the dialysis and functioning graft health states; death is an absorbing health state. Graft survival and patient survival data for imlifidase-enabled transplants were sourced from pooled analyses of imlifidase clinical trials. Patient survival data for dialysis were sourced from the Irish National Kidney Transplant Service database. Quality of life data were sourced from the published literature. Costs were sourced from the published literature and cost databases. Key inputs and assumptions were validated by Irish clinical experts.
RESULTS: Imlifidase-enabled transplantation was found to be dominant compared to dialysis, meaning that imlifidase is associated with greater QALY gain and lower total costs than dialysis over a patient’s lifetime. Imlifidase was also dominant across a range of sensitivity and scenario analyses.
CONCLUSIONS: Imlifidase-enabled kidney transplantation with a deceased donor kidney is a cost-effective treatment strategy compared with lifelong dialysis for highly sensitised adult patients in Ireland.
METHODS: A Markov model was developed to estimate the lifetime costs and quality-adjusted life years (QALYs) for imlifidase-enabled transplantation versus long-term dialysis in Ireland. The model was developed in line with National Centre for Pharmacoeconomics guidelines and consisted of three health states aligned to the local pathway of care: (1) Dialysis (all types); (2) Functioning Graft; and (3) Death. Patients accrue costs, life years, and QALYs in the dialysis and functioning graft health states; death is an absorbing health state. Graft survival and patient survival data for imlifidase-enabled transplants were sourced from pooled analyses of imlifidase clinical trials. Patient survival data for dialysis were sourced from the Irish National Kidney Transplant Service database. Quality of life data were sourced from the published literature. Costs were sourced from the published literature and cost databases. Key inputs and assumptions were validated by Irish clinical experts.
RESULTS: Imlifidase-enabled transplantation was found to be dominant compared to dialysis, meaning that imlifidase is associated with greater QALY gain and lower total costs than dialysis over a patient’s lifetime. Imlifidase was also dominant across a range of sensitivity and scenario analyses.
CONCLUSIONS: Imlifidase-enabled kidney transplantation with a deceased donor kidney is a cost-effective treatment strategy compared with lifelong dialysis for highly sensitised adult patients in Ireland.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE693
Topic
Economic Evaluation
Disease
Surgery, Urinary/Kidney Disorders